Dynamic Advisor Solutions LLC Acquires 370 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Dynamic Advisor Solutions LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,506 shares of the medical research company’s stock after buying an additional 370 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Edwards Lifesciences were worth $1,124,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Park Square Financial Group LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $44,000. Finally, Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $54,000. 79.46% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider now owns 206,900 shares of the company’s stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,153,526.69. The trade was a 27.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,898 shares of company stock worth $3,796,154 over the last 90 days. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

EW has been the topic of a number of research reports. Truist Financial lowered their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a research note on Friday, April 25th. Robert W. Baird boosted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, May 16th. Finally, Citigroup reaffirmed a “buy” rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $80.20.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $73.31 on Wednesday. The firm has a market cap of $43.00 billion, a P/E ratio of 10.47, a P/E/G ratio of 3.77 and a beta of 1.12. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The business’s fifty day moving average is $74.77 and its two-hundred day moving average is $72.96.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.66 earnings per share. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.